0
Abstract: Poster Presentations |

EXPANDING THE APPLICATIONS OF CONTINUOUS POSITIVE AIRWAY PRESSURE IN THE TREATMENT OF ACUTE HYPOXEMIC NON-HYPERCAPNIC RESPIRATORY FAILURE IN THE EMERGENCY DEPARTMENT: ACUTE ASTHMA FREE TO VIEW

Rodolfo Ferrari, MD*; Roberto Lazzari, MD; Daniela Agostinelli, MD; Fabrizio Giostra, MD; Maria Pia Golinelli, MD; Paolo Groff, MD; Federico Lari, MD; Nicola Di Battista, MD
Author and Funding Information

U.O. Pronto Soccorso e Medicina d'Urgenza, Ospedale per gli Infermi, Faenza (RA), Italy


Chest


Chest. 2007;132(4_MeetingAbstracts):513a. doi:10.1378/chest.132.4_MeetingAbstracts.513a
Text Size: A A A
Published online

Abstract

PURPOSE: The application of NonInvasive ventilation (NIV) in Acute Hypoxaemic Respiratory Failure (AHRF) is still controversial. The pathophysiologic rationale supporting Continuous Positive Airway Pressure (CPAP) in nonhypercapnic AHRF is well established: the ability to reexpand alveoli improving oxygenation, allowing the recruitment of underventilated alveoli, enhancing clearance of airway secretions; to get mechanical bronchodilation, lowering airway resistance, reducing the collapse of small airways; to contrast inspiratory treshold imposed by intrinsic Positive End-Expiratory Pressure (PEEP), reducing dynamic hyperinflation, elastic respiratory workload, inspiratory effort; to increase functional residual capacity, favorably shifting the lung on its compliance curve, reducing the work of breathing. We investigated the influence of CPAP as first-line intervention in managing Acute Asthma (AA) patients.

METHODS: We evaluated a series of 10 patients admitted to our Emergency Departments (ED) for AHRF due to AA; 5 treated via Venturi mask, 5 with Boussignac device (PEEP 2-3 cm H2O, FIO2 0.6–0.9). Both groups had epidemiologic, clinical (dyspnoea grade, arterial blood pressure, heart rate, respiratory rate –RR) and arterial blood gas parameters recorded at entry and at 1 hour of treatment, without differences in medical therapy (systemic glucocorticosteroids, inhaled short acting β2-agonists using nebulizing systems).

RESULTS: Both groups showed similar improvement of all considered parameters, with no significant differences. CPAP sorted earlier and more sensible improvement in RR (“Venturi” group 31.2 ± 3.6 at entry, 24 ± 3.8 at 1 hour; “CPAP” group 30.8 ± 2.2 versus 21.8 ± 2.2) and subjective benefit (modified Borg dyspnoea scale: “Venturi” 5.6 ± 2.1 versus 3 ± 1.7; “CPAP” 5.6 ± 2.1 versus 1.8 ± 1.1). No adverse events were recorded.

CONCLUSION: In the ED the early initiation of NIV in AA can be useful: respiratory crises can be averted, respiratory fatigue prevented.

CLINICAL IMPLICATIONS: The overutilization of NIV is also a concern, if its inappropriate application leads to delay of needed intubation and squandering of resources. Carefully selected AA patients, closely monitored by an experienced, motivated staff with appropriate organization, can benefit of noninvasive CPAP treatment.

DISCLOSURE: Rodolfo Ferrari, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543